(NSABP B-47) A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphomide or Four Cycles of Doxorubicin Plus Cyclophosphomide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2 -Low Invasive Breast Cancer
Description: 

The purpose of this study is to learn if adding a targeted therapy, trastuzumab, to standard treatment with chemotherapy for early stage , HER2-low breast cancer, will prevent breast cancer from returning.
A second purpose of this study is to learn if adding trastuzumab to treatment with chemotherapy will help women with HER2 low breast cancer live longer.
Another goal of this study is to find out how the drugs used in this study affect menstrual cycles and if these changes in menstrual cycles have any effect on breast cancer. As part of this study goal, you will be asked to allow blood samples to be collected.

Study Number: 

NCG 195511

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01275677

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.